Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model
article has not abstract
Vyšlo v časopise:
Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model. PLoS Med 5(2): e30. doi:10.1371/journal.pmed.0050030
Kategorie:
Perspective
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.0050030
Souhrn
article has not abstract
Zdroje
1. PalellaFJJrDelaneyKMMoormanACLovelessMOFuhrerJ
1998
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med
338
853
860
2. CardoDMCulverDHCiesielskiCASrivastavaPUMarcusR
1997
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.
N Engl J Med
337
1485
1490
3. CohenMSGayCKashubaADBlowerSPaxtonL
2007
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.
Ann Intern Med
146
591
601
4. FowlerMGLampeMAJamiesonDJKourtisAPRogersMF
2007
Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions.
Am J Obstet Gynecol
197
S3
S9
5. OttenRAAdamsDRKimCNJacksonEPulliumJK
2005
Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates.
J Infect Dis
191
164
173
6. SubbaraoSOttenRARamosAKimCJacksonE
2006
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
J Infect Dis
194
904
911
7. García-LermaJGOttenRAQariSHJacksonECongM
2008
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
PLoS Med
5
e28
doi:10.1371/journal.pmed.0050028
8. BrenchleyJMSchackerTWRuffLEPriceDATaylorJH
2004
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.
J Exp Med
200
749
759
9. BoothCLGerettiAM
2007
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.
J Antimicrob Chemother
59
1047
1056
10. FerradiniLJeanninAPinogesLIzopetJOdhiamboD
2006
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
Lancet
367
1335
1342
11. BrennerBGOliveiraMDoualla-BellFMoisiDDNtemgwaM
2006
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
AIDS
20
F9
F13
12. Gilead Sciences
2007
Truvada package insert. 21-752-GS-20.
Available: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 3 January 2008
13. WangLHBegleyJSt ClaireRL3rdHarrisJWakefordC
2004
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.
AIDS Res Hum Retroviruses
20
1173
1182
14. HawkinsTVeikleyWSt ClaireRL3rdGuyerBClarkN
2005
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
J Acquir Immune Defic Syndr
39
406
411
15. KingTBushmanLKiserJAndersonPLRayM
2006
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.
J Chromatogr B Analyt Technol Biomed Life Sci
843
147
156
16. Van RompayKKBrignoloLLMeyerDJJeromeCTararaR
2004
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Antimicrob Agents Chemother
48
1469
1487
17. AbbasULAndersonRMMellorsJW
2007
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.
PLoS ONE
2
e875
doi:10.1371/journal.pone.0000875
18. GrantRMBuchbinderSCatesWJrClarkeECoatesT
2005
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Science
309
2170
2171
19. PetersonLTaylorDRoddyRBelaiGPhillipsP
2007
Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial.
PLOS Clin Trial
2
e27
doi:10.1371/journal.pctr.0020027
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2008 Číslo 2
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Co dělat při intoleranci statinů?
- Pleiotropní účinky statinů na kardiovaskulární systém
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
Najčítanejšie v tomto čísle
- Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?
- Solving the Mystery of Myelodysplasia
- The Neglected Diseases Section in : Moving Beyond Tropical Infections
- Should Data from Demographic Surveillance Systems Be Made More Widely Available to Researchers?